|
|
|
|
|
|
|
|
Conclusions: Pathogenic BRCA1/2 mutations are common in invasive ovarian cancer and are associated with improved overall survival and response to systemic chemotherapy. BRCA testing should be implemented for all ovarian cancer patients as mutation status has important prognostic and therapeutic clinical utility.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.